A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.
about
Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate CancermiR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD).MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.
P2860
A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@ast
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@en
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@nl
type
label
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@ast
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@en
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@nl
prefLabel
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@ast
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@en
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@nl
P2093
P2860
P1476
A tissue biomarker-based model ...... herapy in RTOG protocol 92-02.
@en
P2093
Alan Pollack
Dayssy A Diaz
Felix Y Feng
Gerald E Hanks
Howard Sandler
James J Dignam
Kyounghwa Bae
Radka Stoyanova
P2860
P304
P356
10.1158/1078-0432.CCR-14-0075
P407
P577
2014-10-07T00:00:00Z